Islet cell transplantation

Ziegler A-G, Kick K, Bonifacio E, et al. Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany. JAMA 2020;323: 339-51. https://doi.org/10.1001/jama.2019.21565

Krischer JP, Liu X, Vehik K, et al. Predicting Islet Cell Autoimmunity and Type 1 Diabetes: An 8-year TEDDY Study Progress Report. Diabetes Care 2019;42(6):1051-60. https://doi.org/10.2337/dc18.2282

Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med 2019;381:603-13. https://doi.org/10.1056/NEJMoa1902226

Walker S, Appari M, Forbes S. Considerations and challenges of islet trans- plantation and future therapies on the horizon. Am J Physiol Endocrinol Metab 2022;322:E109-E117. https://doi.org/10.1152/ajpendo.00310.2021

Shapiro AMJ, Pokrywczynska M, Ricordi C. Clinical pancreatic islet trans- plantation. Nat Rev Endocrinol 2017;13:268-77. https://doi.org/10.10.1038/ nrendo.2016.178

Pybus C. Notes on Suprarenal and Pancreatic Grafting. Lancet Neurol 1924;204:550-1.

Largiadèr F. A long-term functioning human pancreatic islet allotransplant.

Transplantation 1980;29:76-77. https://doi.org/10.1097/00007890-198001000-00017

Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immuno- suppressive regimen. N Engl J Med 2000;343:230-8. https://doi.org.10.1056/NEJM200007273430401

Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clin- ical islet transplantation: 1999-2010. Diabetes Care 2012;35:1436-45. https://doi.org/10.2337/dc12-0063

Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes Care 2012;35:1436-45. https://doi.org/ 10.2337/diabetes.37.4.413

British Transplantation Society. UK Guidelines on Pancreas and Islet Trans- plantation Sept 2019. https://bts.org.uk/wp-content/uploads/2019/09/ FINAL-Pancreas-guidelines-FINAL-version-following-consultation.-Sept- 2019.pdf

Choudhary P, Campbell F, Joule N, Kar P. A Type 1 diabetes technology pathway: consensus statement for the use of technology in Type 1 diabetes. Diabetic Medicine 2019;36(5):531-8. https://doi.org/10.1111/dme.13933

Brooks AM, Walker N, Aldibbiat A, et al. Attainment of metabolic goals in the integrated UK islet transplant program with locally isolated and transported preparations. Am J Transplant 2013;13:3236-43. https://doi.org/10.1111/ajt.12469

Forbes s, Flatt SAJ, Bennett D, et al. The impact of islet mass, number of transplants, and time between transplants on graft function in a national islet transplant program. Am J Transplant 2022;22:154-164. https://doi.org/10.1111/ajy.16785

Hering BJ, Clarke WR, Bridges ND, et al. Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care 2016;39(7):1230-40. https://doi.org/10.2337/dc15-1988

https://citregistry.org/system/files/11th%20Allograft%20report%20May% 2031%202022.pdf

https://clinicaltrials.gov/ct2/show/NCT04786262

Markmann JE, Naji A, Rickels MR, et al. 259-OR. Stem Cell-Derived, Fully Differentiated Islet Cells for Type 1 Diabetes. Diabetes 2022;71(suppl 1):259. https://doi.org/10.2337/db22-259-0R

Ricordi C. SO16: A new niche to replace beta cells. Diabetologia 2022;65 (suppl 1):S196-S197.

Henry RR, Pettus J, Wilensky J, et al. Initial Clinical Evaluation of VC-01TM Combination Product – A Stem Cell-Derived Islet Replacement for Type 1 Diabetes (T1D). Diabetes 2018;67(suppl 1):138-OR.

https://clinicaltrials.gov/ct2/show/NCT02239354

https://clinicaltrials.gov/ct2/show/NCT04678557

Ramzy A, Thompson DM, Ward-Hartstonge KA, et al. Implanted pluripo- tent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive c-peptide in patients with type 1 diabetes. Cell Stem Cell 2021;28:2047- 2061. https://doi.org/10.1016/j.stem.2021.10.003

Shapiro AMJ, Thompson D, Donner TW, et al. Insulin expression and C-peptide in type 1 diabetes subjects with stem cell-derived pancreatic endoderm cells in an encapsulation device. Cell Reports Medicine 2021; 2:100466. https://doi.org.10. 1016/j.xcrm.100466

https://viacyte.com/press-releases/crispr-therapeutics-and-viacyte-inc-an- nounce-first-patient-dosed-in-phase-1-clinical-trial-of-novel-gene-edited- cell-replacement-therapy-for-treatment-of-type-1-diabetes-t1d/